PA8562901A1 - Inhibidores de la fosfatasa - Google Patents

Inhibidores de la fosfatasa

Info

Publication number
PA8562901A1
PA8562901A1 PA20028562901A PA8562901A PA8562901A1 PA 8562901 A1 PA8562901 A1 PA 8562901A1 PA 20028562901 A PA20028562901 A PA 20028562901A PA 8562901 A PA8562901 A PA 8562901A PA 8562901 A1 PA8562901 A1 PA 8562901A1
Authority
PA
Panama
Prior art keywords
phosphatase inhibitors
pyrimido
triazine
useful
relates
Prior art date
Application number
PA20028562901A
Other languages
English (en)
Inventor
Kevin Richard Guertin
Lina Quattrocchio Setti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8562901A1 publication Critical patent/PA8562901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA I EN DONDE R1 Y R2 SE DEFINEN COMO EN LA REIVINDICACION 1 Y LOS CUALES SON DE UTILIDAD PARA LA ELABORACION DE MEDICAMENTOS.
PA20028562901A 2001-12-27 2002-12-24 Inhibidores de la fosfatasa PA8562901A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34393701P 2001-12-27 2001-12-27
US39911002P 2002-07-26 2002-07-26

Publications (1)

Publication Number Publication Date
PA8562901A1 true PA8562901A1 (es) 2003-07-28

Family

ID=26993696

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028562901A PA8562901A1 (es) 2001-12-27 2002-12-24 Inhibidores de la fosfatasa

Country Status (19)

Country Link
US (1) US6642381B2 (es)
EP (1) EP1467996B1 (es)
JP (1) JP4188839B2 (es)
KR (1) KR100601769B1 (es)
CN (1) CN100402530C (es)
AT (1) ATE311388T1 (es)
AU (1) AU2002367190B2 (es)
BR (1) BR0215395A (es)
CA (1) CA2471265C (es)
DE (1) DE60207759T2 (es)
ES (1) ES2252554T3 (es)
JO (1) JO2242B1 (es)
MX (1) MXPA04006266A (es)
PA (1) PA8562901A1 (es)
PE (1) PE20030896A1 (es)
PL (1) PL371180A1 (es)
TW (1) TW200306313A (es)
UY (1) UY27606A1 (es)
WO (1) WO2003055883A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696231B2 (en) * 2001-10-30 2010-04-13 Laboratoires Serono Sa Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs)
ATE427951T1 (de) 2002-11-18 2009-04-15 Hoffmann La Roche Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
AU2005214349B2 (en) * 2004-02-12 2011-11-03 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
AU2007211319B9 (en) 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010083645A1 (en) * 2009-01-21 2010-07-29 Shanghai Targetdrug Co., Ltd PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
GB0022079D0 (en) 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor

Also Published As

Publication number Publication date
MXPA04006266A (es) 2004-09-27
ATE311388T1 (de) 2005-12-15
BR0215395A (pt) 2004-12-07
WO2003055883A1 (en) 2003-07-10
CN1610683A (zh) 2005-04-27
CA2471265A1 (en) 2003-07-10
DE60207759D1 (de) 2006-01-05
DE60207759T2 (de) 2006-08-03
TW200306313A (en) 2003-11-16
EP1467996B1 (en) 2005-11-30
CN100402530C (zh) 2008-07-16
US20030153756A1 (en) 2003-08-14
JP2005517677A (ja) 2005-06-16
AU2002367190A1 (en) 2003-07-15
PE20030896A1 (es) 2003-11-05
EP1467996A1 (en) 2004-10-20
UY27606A1 (es) 2003-06-30
PL371180A1 (en) 2005-06-13
ES2252554T3 (es) 2006-05-16
KR20040068981A (ko) 2004-08-02
JP4188839B2 (ja) 2008-12-03
AU2002367190B2 (en) 2006-10-05
KR100601769B1 (ko) 2006-07-19
US6642381B2 (en) 2003-11-04
JO2242B1 (en) 2004-10-07
CA2471265C (en) 2010-02-09

Similar Documents

Publication Publication Date Title
PA8562901A1 (es) Inhibidores de la fosfatasa
TR200000782T2 (tr) Resorsinol türevleri.
DE69528829D1 (de) Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
SE0101675D0 (sv) Novel composition
NO20073801L (no) Atineoplastiske kombinasjoner
EA199900373A2 (ru) Фармацевтические композиции
IL172825A (en) Preparation of 1,3-diphenylprop-2-en-1-one derivatives
NO20041493L (no) Kjemiske forbindelser.
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
NO20010718L (no) Ny saltform av pantoprazol
PT1473036E (pt) Solvato de hemitartarato de zolpidem
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
SE9801494D0 (sv) Novel use
DE60025494D1 (de) Epothilon zusammensetzungen
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
WO2004020466A8 (en) Protein tyrosine phosphatase inhibitors
DE60106947D1 (de) Oxindolderivate
PL1628979T3 (pl) Związki diaminopirolochinazolinowe jako inhibitory białkowej fosfatazy tyrozynowej
PL1633754T3 (pl) Związki diaminopirolochinazolinowe jako inhibitory białkowych fosfataz tyrozynowych
PT1144348E (pt) Inibidores de lta, hidrolase
MXPA03005400A (es) Metodo para preparacion de 11 (12)-pentadecen-15-olidos.
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.
MA25965A1 (fr) Production de phosphate bicalcique ou de phosphate monocalcique.
GT199900057A (es) Procedimiento para la preparaciòn de ( s , s ) - bencil - 2,8 - diazabiciclo 4.3.0. nonano.